Now live: Pro — the full 13F research suite for serious investorsSee pricing →
RA CAPITAL MANAGEMENT, L.P.

Q1 2024 · 13F-HR

RA CAPITAL MANAGEMENT, L.P.holdings as filed

Filed 2024-05-15 · accession 0001104659-24-062062

$7.80B
Reported value
75
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
04351P101ASNDUSDASCENDIS PHARMA A/S - ADR$1.53B19.6%10,108,400CommonSOLE
92243G108PCVXVAXCYTE INC$560.4M7.19%8,203,754CommonSOLE
52490G102LEGNLEGEND BIOTECH CORP-ADR$384.8M4.93%6,861,097CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$345.1M4.42%9,165,652CommonSOLE
008064107AEROVATE THERAPEUTICS INC$244.4M3.13%8,263,982CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$231.0M2.96%5,330,412CommonSOLE
30050B101EVHEVOLENT HEALTH INC - A$188.1M2.41%5,736,132CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA CO NV$186.0M2.38%7,864,000CommonSOLE
78349D107RXSTRXSIGHT INC$177.6M2.28%3,442,825CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$170.8M2.19%10,416,609CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$162.5M2.08%8,909,091CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$160.9M2.06%5,051,511CommonSOLE
09062X103BIIBBIOGEN INC$159.7M2.05%740,727CommonSOLE
713317105PEPGPEPGEN INC$157.1M2.01%10,689,545CommonSOLE
374163103GERNGERON CORP$152.5M1.96%46,202,425CommonSOLE
282559103ETNBGBP89BIO INC$148.6M1.91%12,766,948CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$140.7M1.80%4,954,779CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$131.4M1.69%1,977,901CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$129.0M1.65%7,809,852CommonSOLE
65487U108NKTXNKARTA INC$116.8M1.50%10,805,129CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$112.3M1.44%18,202,009CommonSOLE
82835W108SPRYARS PHARMACEUTICALS INC$111.0M1.42%10,860,977CommonSOLE
359616109FULCFULCRUM THERAPEUTICS INC$109.6M1.41%11,609,704CommonSOLE
925050106VRNAVERONA PHARMA PLC - ADR$101.7M1.30%6,317,990CommonSOLE
52635N103LENZLENZ THERAPEUTICS INC$93.3M1.20%4,178,823CommonSOLE
45720L107INBXUSDINHIBRX INC$91.9M1.18%2,629,837CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$83.8M1.07%3,282,180CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$79.8M1.02%1,000,000CommonSOLE
54300N103LONGBOARD PHARMACEUTICALS IN$71.0M0.91%3,289,119CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$70.0M0.90%2,333,000CommonSOLE
G3855L106GHRSGH RESEARCH PLC$66.6M0.85%6,251,714CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$64.7M0.83%1,510,362CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$62.6M0.80%4,850,984CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$62.1M0.80%4,413,150CommonSOLE
00509G209ABOSACUMEN PHARMACEUTICALS INC$60.5M0.78%14,932,063CommonSOLE
46565G1045E7ITEOS THERAPEUTICS INC$60.3M0.77%4,417,259CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$57.7M0.74%4,330,446CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$54.6M0.70%204,500CommonSOLE
929033108VOR BIOPHARMA INC$53.9M0.69%22,748,880CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$50.5M0.65%828,380CommonSOLE
M96088105URGNUROGEN PHARMA LTD$46.3M0.59%3,083,430CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$45.9M0.59%6,045,351CommonSOLE
23285D109CTKBCYTEK BIOSCIENCES INC$45.7M0.59%6,809,404CommonSOLE
12529R107CCCCC4 THERAPEUTICS INC$39.9M0.51%4,878,000CommonSOLE
95075A107HOWLWEREWOLF THERAPEUTICS INC$39.8M0.51%6,144,881CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$37.3M0.48%2,122,465CommonSOLE
28658R106CLYMELIEM THERAPEUTICS INC$36.0M0.46%13,150,849CommonSOLE
004890109ACRVACRIVON THERAPEUTICS INC$34.4M0.44%4,810,508CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$31.2M0.40%10,872,503CommonSOLE
10170A100BOLDBOUNDLESS BIO INC$31.1M0.40%2,180,631CommonSOLE
556099109MGNXMACROGENICS INC$30.6M0.39%2,082,021CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$30.1M0.39%5,755,050CommonSOLE
23256X100CYBIN INC$24.0M0.31%58,139,535CommonSOLE
02157Q109ANROALTO NEUROSCIENCE INC$21.3M0.27%1,385,491CommonSOLE
15713L109CRVOCERVOMED INC$20.1M0.26%861,573CommonSOLE
92243A200VXRTVAXART INC$20.0M0.26%15,384,615CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC-ADR$19.9M0.26%800,000CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$19.4M0.25%938,591CommonSOLE
88427A107THIRD HARMONIC BIO INC$19.2M0.25%2,033,056CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$19.1M0.24%1,281,000CommonSOLE
81749D107SERASERA PROGNOSTICS INC-A$18.4M0.24%2,024,221CommonSOLE
59102M104MGXMETAGENOMI INC$18.4M0.24%1,744,415CommonSOLE
N44445109IMTXIMMATICS NV$18.4M0.24%1,750,000CommonSOLE
037326105ANTXAN2 THERAPEUTICS INC$18.0M0.23%5,551,295CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$18.0M0.23%6,250,000CommonSOLE
09203E105BDTXBLACK DIAMOND THERAPEUTICS I$17.9M0.23%3,525,754CommonSOLE
007002108TORCEURADICET BIO INC$17.7M0.23%7,541,000CommonSOLE
04335A105ARVNARVINAS INC$17.4M0.22%421,348CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$10.4M0.13%660,938CommonSOLE
16934W106CMRXEURCHIMERIX INC$9.3M0.12%8,800,000CommonSOLE
4495851081K0IGM BIOSCIENCES INC$9.0M0.12%937,500CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$6.6M0.08%791,359CommonSOLE
N2451R105CVACCUREVAC NV$6.0M0.08%1,965,707CommonSOLE
90466Y103UNICYCIVE THERAPEUTICS INC$4.8M0.06%3,470,688CommonSOLE
N62509117NAMSWNEWAMSTERDAM PHARMA CO NV-27$3.7M0.05%333,333CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.